American biopharmaceutical company at Cambridge in Massachusetts, founded in 2008 out of work on cyclic peptide chemistry and listed in New York before it was bought by UCB in 2020. Developed zilucoplan, a synthetic macrocyclic peptide inhibitor of complement component five given by subcutaneous injection and approved for generalised myasthenia gravis, together with a peptide discovery platform aimed at targets normally reached only by biological medicines.
Aucun commentaire disponible.
Laissez votre note & commentaire